Literature DB >> 11860167

Urinary desmosine excretion in acute exacerbations of COPD: a preliminary report.

D Fiorenza1, S Viglio, A Lupi, J Baccheschi, C Tinelli, R Trisolini, R Iadarola, M Luisetti, G L Snider.   

Abstract

Desmosine (DES) is an elastin-derived, cross-link amino acid, which is not metabolized; hence, its urinary levels reflect elastin breakdown. We hypothesized that elastin degradation should increase as a result of increased lung inflammation during an acute exacerbation of COPD and should decrease after recovery. To test this hypothesis we measured DES in three urine samples from nine COPD subjects during the first 5 days of an acute exacerbation and at 2 months after recovery. We also measured forced expiratory volume in 1 sec (FEV1) to monitor the effects ofthe exacerbation on ventilatory function. The mean (SD) FEV1 was 45 (15)% predicted during the exacerbation and 57.8 (16)% predicted 2 months later (P=0.00001). The mean (SD) DES excretion was 25.3 (9) microg g(-1) creatinine at day 1;23.5 (9) at day 3 and 24 (9) at day 5 of the exacerbation. The mean (SD) urinary DES excretion 60 days after discharge was 20.9 (7) microg g(-1) creatinine (P=0.049) in comparison with the mean of the three acute-phase values. The size of the increase in desmosine excretion during exacerbation is small, 3.2 microg g(-1) creatinine or 16% of the recovery desmosine value. We conclude that there is a small but statistically significant increase in lung elastin breakdown in the body during an acute exacerbation of COPD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11860167     DOI: 10.1053/rmed.2001.1224

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Intermittent Hypoxia Contributes to the Lung Damage by Increased Oxidative Stress, Inflammation, and Disbalance in Protease/Antiprotease System.

Authors:  I Tuleta; F Stöckigt; U R Juergens; C Pizarro; J W Schrickel; G Kristiansen; G Nickenig; D Skowasch
Journal:  Lung       Date:  2016-10-13       Impact factor: 2.584

Review 2.  Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature.

Authors:  Ho Il Yoon; Don D Sin
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

3.  Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.

Authors:  Theresa A Laguna; Brandie D Wagner; Barry Starcher; Heidi K Luckey Tarro; Shelley A Mann; Scott D Sagel; Frank J Accurso
Journal:  Pediatr Pulmonol       Date:  2012-03-19

4.  Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.

Authors:  Sara Ongay; Marijke Sikma; Peter Horvatovich; Jos Hermans; Bruce E Miller; Nick H T Ten Hacken; Rainer Bischoff
Journal:  Chronic Obstr Pulm Dis       Date:  2016-03-01

5.  Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?

Authors:  Jerome O Cantor; Joseph M Cerreta; Marcos Ochoa; Shuren Ma; Ming Liu; Gerard M Turino
Journal:  Lung       Date:  2010-12-14       Impact factor: 2.584

6.  High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine.

Authors:  Michel Boutin; Carl Berthelette; François G Gervais; Mary-Beth Scholand; John Hoidal; Mark F Leppert; Kevin P Bateman; Pierre Thibault
Journal:  Anal Chem       Date:  2009-03-01       Impact factor: 6.986

7.  Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease.

Authors:  Jeffrey T J Huang; Rekha Chaudhuri; Osama Albarbarawi; Alun Barton; Christal Grierson; Petra Rauchhaus; Christopher J Weir; Martina Messow; Nicola Stevens; Charles McSharry; Giora Feuerstein; Somnath Mukhopadhyay; Jeffrey Brady; Colin N A Palmer; Douglas Miller; Neil C Thomson
Journal:  Thorax       Date:  2012-01-16       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.